Larimar Therapeutics | 10-Q: FY2025 Q3 Revenue: USD 0

Revenue: As of FY2025 Q3, the actual value is USD 0.

EPS: As of FY2025 Q3, the actual value is USD -0.61, missing the estimate of USD -0.403.

EBIT: As of FY2025 Q3, the actual value is USD -49.5 M.

Segment Revenue

• Research and Development Expenses: $44.9 million for the three months ended September 30, 2025, compared to $13.9 million for the same period in 2024. $94.9 million for the nine months ended September 30, 2025, compared to $46.5 million for the same period in 2024.
• General and Administrative Expenses: $4.6 million for the three months ended September 30, 2025, compared to $4.3 million for the same period in 2024. $13.6 million for the nine months ended September 30, 2025, compared to $13.1 million for the same period in 2024.

Operational Metrics

• Net Loss: $47.7 million for the three months ended September 30, 2025, compared to $15.5 million for the same period in 2024. $103.2 million for the nine months ended September 30, 2025, compared to $51.8 million for the same period in 2024.
• Loss from Operations: $49.5 million for the three months ended September 30, 2025, compared to $18.3 million for the same period in 2024. $108.5 million for the nine months ended September 30, 2025, compared to $59.6 million for the same period in 2024.

Cash Flow

• Net Cash Used in Operating Activities: - $74.7 million for the nine months ended September 30, 2025, compared to - $48.9 million for the same period in 2024.
• Net Cash Provided by Investing Activities: $66.3 million for the nine months ended September 30, 2025, compared to - $104.6 million for the same period in 2024.
• Net Cash Provided by Financing Activities: $65.3 million for the nine months ended September 30, 2025, compared to $161.8 million for the same period in 2024.

Unique Metrics

• Stock-Based Compensation Expense: $1.8 million for the three months ended September 30, 2025, compared to $2.0 million for the same period in 2024. $5.4 million for the nine months ended September 30, 2025, compared to $6.4 million for the same period in 2024.

Future Outlook and Strategy

• Core Business Focus: Larimar Therapeutics, Inc. plans to provide an update on regulatory discussions and open label study status in the first quarter of 2026. The company targets a Biologics License Application (BLA) submission seeking accelerated approval in the second quarter of 2026.
• Non-Core Business: The company continues to qualify sites globally and prepare for study initiation and patient enrollment for the global phase 3 protocol.